overt mitochondrial dysfunction
degree of mitochondrial dysfunction
detectable mitochondrial dysfunction
mitochondrial morphology
monogenic PD patients
extreme cohorts of idiopathic PD patients
Systems Medicine of Mitochondrial Parkinson’s Disease
silico models
derived dopaminergic neurons
culture of iPSC
Personalised computational models of dopaminergic neuronal metabolism
humanised mouse models
lead compounds
new new targets
subset of Parkinson’s disease
ambitious project
drug development
suite of personalised
striatally transplants of iPSC
systems biomedicine approach
Multi-modal phenotypic characterisation of cohorts
novel drug candidates capable
D microfluidic cell culture product
situ striatal neurochemistry
metabolomic assay optimisation
iPSCs
bioanalytical screen
high temporal resolution
prioritising pathways
industrial quality
induced pluripotent stem cells
mechanistic interpretation
overall objective
experienced multidisciplinary consortium
monitoring motor behaviour
selected subjects
candidate neuroprotectants
progression of neurodegeneration
response
discovery
SysMedPD
controls
experimental results
anchor
people